Gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer.

Author: Yilong WU ¹ ; Xuening YANG ; Jinji YANG ; Yujuan HUANG
Author Information

1. The Lung Cancer Research Institute and Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, P.R.China.
Publication Type:Journal Article
From: Chinese Journal of Lung Cancer 2004;7(4):318-320
CountryChina
Language:Chinese
Abstract:
BACKGROUNDTo explore the experience of gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer (NSCLC).
METHODSThe unpublished data of gefitinib for advanced NSCLC in 7 hospitals were collected. The detailed data from Guangdong Provincial People's Hospital were analyzed.
RESULTSA total of 282 patients with advanced NSCLC was treated with gefitinib from July 2001 to December 2003. Response rate was 22.2%-47.7%, disease control rate 62.6%-81.8%. No severe side effects were surveyed.
CONCLUSIONSGefitinib can be used safely and effectively in Chinese patients with advanced NSCLC.